News

Danville organization invests in Blacksburg’s CytoRecovery medical cell sorting company

Danville’s investment might mean a CytoRecovery presence in Danville, such as office operations or an internship at Danville Community College. CytoRecovery’s cell sorting could improve understanding of disease and development of drugs.

CytoRecovery, an early-stage company that invented and patented less invasive cell sorting, will be able to bring its cell research platform to market after an investment from a Danville-based organization.

This means Blacksburg-based CytoRecovery could have a presence in Danville, according to Stephen Turner, the company’s CEO.

“CytoRecovery looks forward to participating in the Danville economy, and is currently reviewing several options to do so, including establishing branch office operations and a collaboration to develop a life science internship program with Danville Community College,” Turner said in an email.

Danville’s The Launch Place, an organization that works to support entrepreneurs and raise capital, announced Dec. 1 an investment of $250,000 in Cyto Recovery.

This funding “will help CytoRecovery commercialize its flagship cell sorting platform for medical research,” a release said.

Specifically, CytoRecovery will bring its Cyto R1 platform to the market after five years of development.

This product “improves the speed and precision of the sorting, enrichment and recovery of live cells from tissue and other biological samples,” the release said. “Its technology can quickly isolate, enrich and recover rare, distinct cell populations, enabling their downstream analysis and therapeutic response.”

This investment comes after the company’s inaugural sale of Cyto R1 to University of California at Irvine researchers in September.

“Having just installed our first system at a major California-based stem cell research center, we have a growing pipeline of prospective customers,” Turner said in the release.

CytoRecovery’s faster and less invasive cell sorting could improve understanding of disease, development of drugs, and determination of effective therapies.

The Launch Place team chose CytoRecovery for this funding because they believed in both the technology and in Turner himself, who has founded several life science companies, said the release.

CytoRecovery’s platform outperforms existing cell separation methods, said Eva Doss, president and CEO of The Launch Place.

“The technology also enables new possibilities in cell research by having broad applications in the fields of oncology, regenerative medicine, hyper-personalized medicine, and pharmaceutical research and development,” Doss said in the release.

The two organizations have an existing relationship. In 2018, CytoRecovery received a $75,000 investment from The Launch Place, which guided the startup’s development and provided instructions to other sources of funding and potential customers, the release said.

A CytoRecovery branch office operation in Danville would be its first location outside of Blacksburg.

Read more here.

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep